These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34592051)

  • 1. Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis.
    Patel S; Martin MT; Flamm SL
    Liver Int; 2021 Dec; 41(12):3024-3027. PubMed ID: 34592051
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and virologic failure to direct-acting antivirals.
    Ruiz-Boy S; Rodriguez-Reyes M; Sotoca-Momblona JM
    Med Clin (Barc); 2021 Jul; 157(2):85-86. PubMed ID: 32807510
    [No Abstract]   [Full Text] [Related]  

  • 3. Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection.
    Karimi-Sari H; Rezaee-Zavareh MS; Falade-Nwulia O; Lim JK
    J Hepatol; 2022 Oct; 77(4):1215-1217. PubMed ID: 35798132
    [No Abstract]   [Full Text] [Related]  

  • 4. Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.
    Bourlière M; Gordon SC; Schiff ER; Tran TT; Ravendhran N; Landis CS; Hyland RH; Stamm LM; Zhang J; Dvory-Sobol H; Subramanian GM; Brainard DM; McHutchison JG; Serfaty L; Thompson AJ; Sepe TE; Curry MP; Reddy KR; Manns MP
    Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):559-565. PubMed ID: 29859740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.
    Heo YA; Deeks ED
    Drugs; 2018 Apr; 78(5):577-587. PubMed ID: 29546556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).
    Wilson E; Covert E; Hoffmann J; Comstock E; Emmanuel B; Tang L; Husson J; Chua J; Price A; Mathur P; Rosenthal E; Kattakuzhy S; Masur H; Kottilil S
    J Hepatol; 2019 Sep; 71(3):498-504. PubMed ID: 31173815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
    Bourlière M; Gordon SC; Flamm SL; Cooper CL; Ramji A; Tong M; Ravendhran N; Vierling JM; Tran TT; Pianko S; Bansal MB; de Lédinghen V; Hyland RH; Stamm LM; Dvory-Sobol H; Svarovskaia E; Zhang J; Huang KC; Subramanian GM; Brainard DM; McHutchison JG; Verna EC; Buggisch P; Landis CS; Younes ZH; Curry MP; Strasser SI; Schiff ER; Reddy KR; Manns MP; Kowdley KV; Zeuzem S;
    N Engl J Med; 2017 Jun; 376(22):2134-2146. PubMed ID: 28564569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry.
    Onofrio FQ; Cooper C; Borgia SM; Vachon ML; Ramji A; Lilly LB; Wong A; Booth J; Sattar I; Morales H; Lee S; Conway B; Feld JJ
    Clin Infect Dis; 2021 Jun; 72(11):e799-e805. PubMed ID: 33677545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry.
    Wong YJ; Kumar R; Kumar R; Tan J; Liu CH; Hui VK; Tan SS; Kao JH; Wong GH; Thurairajah PH
    J Gastroenterol Hepatol; 2022 Aug; 37(8):1642-1644. PubMed ID: 35723645
    [No Abstract]   [Full Text] [Related]  

  • 10. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
    Sarrazin C; Cooper CL; Manns MP; Reddy KR; Kowdley KV; Roberts SK; Dvory-Sobol H; Svarovskia E; Martin R; Camus G; Doehle BP; Stamm LM; Hyland RH; Brainard DM; Mo H; Gordon SC; Bourliere M; Zeuzem S; Flamm SL
    J Hepatol; 2018 Dec; 69(6):1221-1230. PubMed ID: 30098373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial.
    Gupta N; Manirambona L; Shumbusho F; Kabihizi J; Murangwa A; Serumondo J; Makuza JD; Nsanzimana S; Muvunyi CM; Mukabatsinda C; Musabeyezu E; Camus G; Grant PM; Kateera F
    Lancet Gastroenterol Hepatol; 2022 Jun; 7(6):542-551. PubMed ID: 35248212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection.
    Indolfi G; Kelly D; Nebbia G; Iorio R; Mania A; Giacomet V; Szenborn L; Shao J; Sang Yue M; Hsueh CH; Parhy B; Kersey K; Mangia A; Pawlowska M; Bansal S
    Hepatology; 2022 Aug; 76(2):445-455. PubMed ID: 35112372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.
    Ruiz-Cobo JC; Llaneras J; Forns X; Gallego Moya A; Conde Amiel I; Arencibia A; Diago M; García-Samaniego J; Castellote J; Llerena S; Rodríguez-Seguel E; Mateos B; Rodríguez M; Rosales Zabal JM; Fernández I; Calleja JL; Morillas RM; Montoliu S; Andrade RJ; Badia Aranda E; Hernández-Guerra M; Maté CJ; González-Santiago JM; de Cuenca B; Bernal-Monterde V; Delgado M; Turnes J; Lens S; Buti M
    Aliment Pharmacol Ther; 2024 Jul; 60(2):201-211. PubMed ID: 38695095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure.
    Garcia-Cehic D; Rando A; Rodriguez-Frias F; Gregori J; Costa JG; Carrión JA; Macenlle R; Pamplona J; Castro-Iglesias A; Cañizares A; Tabernero D; Campos C; Buti M; Esteban JI; Quer J
    J Viral Hepat; 2021 Sep; 28(9):1319-1324. PubMed ID: 33720484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.
    Papaluca T; Roberts SK; Strasser SI; Stuart KA; Farrell G; MacQuillan G; Dore GJ; Wade AJ; George J; Hazeldine S; O'Beirne J; Wigg A; Fisher L; McGarity B; Sawhney R; Sinclair M; Thomas J; Valiozis I; Weltman M; Wilson M; Woodward A; Ahlenstiel G; Haque M; Levy M; Prewett E; Sievert W; Sood S; Tse E; Valaydon Z; Bowden S; Douglas M; New K; O'Keefe J; Hellard M; Doyle J; Stoove M; Thompson AJ
    Clin Infect Dis; 2021 Nov; 73(9):e3288-e3295. PubMed ID: 32887983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Glecaprevir/Pibrentasvir + Sofosbuvir + Ribavirin as a salvage regimen after Sofosbuvir + Velpatasvir + Voxilaprevir re-treatment failure].
    Tergast TL; Kordecki N; Ohlendorf V; Beier C; Sandmann L; Wedemeyer H; Cornberg M; Maasoumy B
    Z Gastroenterol; 2022 Jun; 60(6):959-962. PubMed ID: 34666403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility, safety, efficacy and potential scaling-up of sofosbuvir-based HCV treatment in Central and West Africa: (TAC ANRS 12311 trial).
    Lacombe K; Moh R; Chazallon C; Lemoine M; Sylla B; Fadiga F; Le Carrou J; Marcellin F; Kouanfack C; Ciaffi L; Sartre MT; Sida MB; Diallo A; Gozlan J; Seydi M; Cissé V; Danel C; Girard PM; Toni TD; Minga A; Boyer S; Carrieri P; Attia A;
    Sci Rep; 2024 May; 14(1):10244. PubMed ID: 38702350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
    Duerr M; Schrezenmeier EV; Lehner LJ; Bergfeld L; Glander P; Marticorena Garcia SR; Althoff CE; Sack I; Brakemeier S; Eckardt KU; Budde K; Halleck F
    BMC Nephrol; 2019 Feb; 20(1):36. PubMed ID: 30717681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IFNL4 Genotype Is Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir.
    O'Brien TR; Kottilil S; Pfeiffer RM
    Gastroenterology; 2017 Dec; 153(6):1694-1695. PubMed ID: 29107709
    [No Abstract]   [Full Text] [Related]  

  • 20. Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment study.
    Ruane P; Strasser SI; Gane EJ; Hyland RH; Shao J; Dvory-Sobol H; Tran T; Stamm LM; Brainard DM; Nyberg L; Shafran S
    J Viral Hepat; 2019 Jun; 26(6):770-773. PubMed ID: 30663168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.